Edition:
United Kingdom

People: Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

4.05USD
23 Aug 2019
Change (% chg)

$-0.21 (-4.93%)
Prev Close
$4.26
Open
$4.23
Day's High
$4.37
Day's Low
$4.03
Volume
341,337
Avg. Vol
356,802
52-wk High
$10.44
52-wk Low
$3.51

Butler, John 

Mr. John P. Butler serves as President, Chief Executive Officer and Director of Akebia Therapeutics, Inc. Mr. Butler joined Akebia as a director in July 2013 and was appointed as the President and Chief Executive Officer of Akebia in September 2013. Prior to joining Akebia, from 2011 until 2013, Mr. Butler served as the Chief Executive Officer of Inspiration Biopharmaceuticals, Inc., a company that filed for protection under Chapter 11 of the U.S. Bankruptcy Code in October 2012 prior to the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013 for total aggregate consideration that could exceed $1 billion. From 1997 to 2011, Mr. Butler held various positions at Genzyme Corporation, now Sanofi Genzyme, most recently serving as President of the company’s rare genetic diseases business. From 2002 until 2010, Mr. Butler led Genzyme’s renal division. Prior to his work at Genzyme, Mr. Butler held sales and marketing positions at Amgen and Hoffmann-La Roche. Mr. Butler currently serves on the Board of Directors of Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE). From 2013 to 2016, Mr. Butler served on the Board of Directors of Relypsa, Inc. From 2015 to 2017, Mr. Butler served on the Board of Directors of Keryx and was Chairman of Keryx’s Board of Directors from 2016 to 2017. Mr. Butler formerly served as a Chairman of the Board of Trustees of the American Kidney Fund. Mr. Butler received a B.A. in Chemistry from Manhattan College and an M.B.A. degree from Baruch College, City University of New York. We believe that Mr. Butler is qualified to serve on our Board of Directors due to his industry e dxperience in the biotechnology sector, particularly his experience working in the renal disease area.

Basic Compensation

Total Annual Compensation, USD 594,720
Restricted Stock Award, USD 1,271,270
Long-Term Incentive Plans, USD --
All Other, USD 1,605,080
Fiscal Year Total, USD 3,471,070

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Adrian Adams

133,436

John Butler

3,471,070

Jason Amello

1,091,020

Nicole Hadas

--

Steven Burke

--

Michel Dahan

1,276,790
As Of  31 Dec 2018